Proposal to list patient warming and cooling medical devices supplied by EBOS Group Limited and Surgico Medical & Surgical Ltd
11 February 2019
What we’re proposing
PHARMAC is seeking feedback on a proposal to list a range of patient warming and cooling products in Part III of Section H of the Pharmaceutical Schedule from 1 April 2019 through provisional agreements with EBOS Group Limited (“EBOS”) and Surgico Medical & Surgical Ltd (“Surgico”).
Consultation closes at 4pm on Friday 1 March 2019 and feedback can be emailed to firstname.lastname@example.org.
What would the effect be?
From 1 April 2019 EBOS and Surgico’s ranges of patient warming and cooling products would be listed under proposed national agreements for all DHB Hospitals to purchase under, subject to consultation and approval by PHARMAC’s Board or delegate (“Agreements”).
The Agreements would not be for sole supply. DHBs would continue to be able to purchase other suppliers’ brands of patient warming and cooling products.
The Agreements would supersede any existing DHB contracts with EBOS and Surgico for the products included in the Agreements. Any medical device listed in the Agreements and purchased by a DHB would be at the price, terms and conditions stated in the Agreements, effective from the date of listing on the Pharmaceutical Schedule.
Under the Agreements each of the suppliers would provide appropriate educational services that would be tailored to the individual needs of DHBs, in formats and at times as required by DHBs.
Pricing for the medical devices in the Agreements, subject to any prior termination of the Agreements, would not be increased without prior consultation and approval by PHARMAC.
Who we think will be interested
- Suppliers and Wholesalers
- DHB Staff
- Clinical Engineers
- Anaesthetists and Anaesthetic Technicians
- DHB procurement and warehousing personnel
- ICU technicians
About the medical devices
Patient warming and cooling products
Patient warming and cooling products are used to assist regulating a patient’s core body temperature when a patient is unable to self-regulate their body temperature. Patient warming and cooling products are commonly used in surgical and intensive care clinical settings.
Why we’re proposing this
In 2018 PHARMAC issued Requests for Proposals (“RFPs”) for patient warming and cooling products. These RFPs were for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
PHARMAC has been working with suppliers who responded to the RFP to seek provisional agreements and these proposals are the latest to arise from this process. We expect to consult on further proposed agreements with suppliers of patient warming and cooling products over the next coming months.
Details about our proposal
The proposal would result in the following Pharmaceutical Schedule listings from 1 April 2019:
Pricing has been made available to appropriate DHB personnel.
To provide feedback
Send us an email: email@example.com by 4pm on Friday 1 March 2019.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.
Last updated: 11 February 2019